Rx hormone track

NP Thyroid

Name: NP Thyroid: What the Research Actually Shows
Creator: Peptide Health Lab

Also known as: Desiccated thyroid extract, Natural desiccated thyroid, Porcine thyroid extract

Regulatory status: Rx via compounding
Evidence grade: Human RCT evidence

Last reviewed August 2, 2026 · 10 sources

What NP Thyroid is and how it works

NP Thyroid is a desiccated thyroid extract: thyroid hormone prepared from porcine thyroid glands and pressed into an oral tablet. What distinguishes it from levothyroxine is composition rather than mechanism: levothyroxine supplies thyroxine (T4) alone and relies on the body's deiodinase enzymes to convert it into the more biologically active triiodothyronine (T3), while desiccated extract supplies both hormones directly. In the randomized literature it is therefore grouped with levothyroxine-plus-liothyronine as a triiodothyronine-containing therapy, and studied against levothyroxine monotherapy on that basis.^[8]^[7]

The clinical problem it is used for is straightforward. Hypothyroidism is thyroid hormone deficiency, most often from Hashimoto thyroiditis, and its consequences are not cosmetic: untreated, it can progress to myxedema coma, a condition requiring intensive care with a mortality rate reported up to 30%. First-line treatment is synthetic levothyroxine titrated to normalize serum thyrotropin.^[10] Thyrotropin, or TSH, is the pituitary's feedback signal, and it is what makes this therapy manageable: the prescriber is not guessing at a dose but adjusting until a measured feedback loop settles.

That is also why this page cannot tell anyone anything useful about amounts. Two people of the same weight and diagnosis can require substantially different replacement, and the same person's requirement changes with age, pregnancy, body weight, other medications, and gastrointestinal absorption. The therapy is inseparable from the lab work that steers it, and the lab work requires a prescriber.^[2]

What the research actually shows

Desiccated thyroid extract has been tested against levothyroxine in properly designed randomized trials. That puts it in a completely different evidential category from most compounds discussed in the same conversations.

The 2013 crossover trial randomized 70 adults with primary hypothyroidism, already stable on levothyroxine for at least six months, to 16 weeks of desiccated thyroid extract and 16 weeks of levothyroxine in random order, double-blind. There were no differences in symptoms or neurocognitive measurements between the two therapies. Patients lost about 3 lb while on desiccated extract. At the end, 48.6% preferred the extract, 18.6% preferred levothyroxine, and 32.9% had no preference; among those who preferred it, subjective symptom scores were significantly better on the general health and thyroid symptom questionnaires. The authors' conclusion was that desiccated thyroid extract did not produce a significant improvement in quality of life, but did cause modest weight loss and was preferred by nearly half the participants.^[3]

The 2021 three-arm trial randomized 75 hypothyroid patients through levothyroxine, levothyroxine plus liothyronine, and desiccated thyroid extract, 22 weeks each, double-blind. Thyrotropin stayed within the reference range in every arm. There were no differences on any primary or secondary outcome except a minor increase in heart rate on desiccated extract, and no overall difference in treatment preference. The one signal came from a prespecified subgroup: the third of patients who were most symptomatic while on levothyroxine showed a strong preference for the triiodothyronine-containing treatments, with better scores on the symptom questionnaire, general health questionnaire, depression inventory, and visual memory.^[8]

The wider combination-therapy literature agrees. A joint consensus process noted that 14 clinical trials have not demonstrated a consistent benefit of combining levothyroxine with liothyronine, acknowledged that patients continue to report benefit, and concluded there is genuine equipoise for a better-designed trial.^[7] A systematic review of 18 studies found no difference between combination and monotherapy in clinical status, quality of life, psychological distress, depressive symptoms, or fatigue, at low-to-moderate certainty, while finding 43% of patients preferring combination therapy against 23% preferring monotherapy.^[9]

Guideline bodies have taken the obvious position. The American Thyroid Association task force reviewed levothyroxine, thyroid extracts, synthetic combination therapy, liothyronine, compounded thyroid hormones, and thyroid hormone analogs, and concluded that levothyroxine should remain the standard of care, with no consistently strong evidence that any alternative improves health outcomes.^[4]

Where the evidence is weak

Preference is not the same as benefit, and both readings are being overstated. A trial where half the participants prefer a treatment whose measured outcomes are identical is a genuinely interesting result. It does not establish superiority, and the trials were not designed to explain the preference. Blinding was maintained; weight change, heart rate, and residual triiodothyronine exposure are all candidate explanations, and none has been isolated.^[3]^[8]

The trials are short and small. Sixteen and twenty-two weeks per arm, in 70 and 75 patients respectively. Hypothyroidism is treated for decades. Nothing in this literature speaks to bone, cardiac, or mortality outcomes over that horizon, and the trials were not powered to detect them if they existed.

The subgroup result is a hypothesis. The strong preference for triiodothyronine-containing therapy among the most symptomatic third of patients is the most clinically suggestive finding in the field. It is also a subgroup of 75, identified within a trial whose primary comparisons were null.^[8] The consensus document exists precisely because that hypothesis has not yet been tested in a trial designed around it.^[7]

Long-term safety of low-normal thyrotropin has never been randomized. What exists is prospective cohort evidence, and it is not reassuring: low thyrotropin in older people predicted atrial fibrillation over 10 years;^[1] people on thyroid hormone therapy carried far higher rates of biochemical thyrotoxicosis than untreated peers;^[5] and subclinical hyperthyroidism was associated with faster femoral neck bone loss across six cohorts.^[6] Cohort data cannot prove that a deliberately suppressed target causes those outcomes. It is, however, the only evidence there is, and it points one way.

Product-level consistency is a live issue rather than a settled one. Desiccated thyroid is a biologically derived product, and NP Thyroid itself has been recalled in both directions: superpotent lots in 2020, subpotent lots later that year and again in 2021. The strengths, percentages and adverse-event counts are set out under legal and regulatory status below. There is no published trial that isolates what lot-to-lot variation does to a person's thyrotropin over time, which is one more reason this is a monitored therapy rather than a stable one.

Legal and regulatory status

NP Thyroid is a prescription-only thyroid hormone product. It cannot be obtained without a prescriber, and its use requires periodic laboratory testing to be practiced safely. That is a clinical fact about the drug class, not a barrier to be routed around.

A note on the status badge above. This library sorts every compound into one of three regulatory buckets, and none of the three fits this product cleanly. NP Thyroid is not FDA approved, so the approved bucket is wrong; it is a prescription therapy in routine clinical use, so the research-only bucket is wrong too. It carries the prescription bucket by elimination. Read that badge as "prescription, not FDA approved," because the FDA's position is specifically that these products are not eligible for the compounding exemptions either. The paragraphs below are the accurate statement of its status; the badge is a three-word approximation of them.

Its regulatory position differs from levothyroxine's in a way that is easy to miss, and it is not the benign legacy status it is usually described as. The FDA does not treat desiccated thyroid extract as an old drug grandfathered past the modern approval framework. It treats it as an unapproved biological product marketed without the license the law requires. The agency's reasoning is that the extract necessarily contains thyroglobulin, a protein of 2,770 amino acids, which brings these products within the statutory definition of a biological product; on that reading, since March 2020 the only marketing application available for one has been a biologics license application under section 351 of the Public Health Service Act.

On August 6, 2025 the FDA wrote to manufacturers, importers and distributors of animal-derived thyroid products stating that such a license is required for the products to be legally marketed in the United States, that no approved license exists for any product currently on the market, and that the agency intended to take action against them, while allowing up to twelve months for patients to be transitioned to an approved thyroid hormone replacement product. The letter addressed the category rather than named firms, and the agency's public materials identify Armour Thyroid, NP Thyroid, Nature-Thyroid and Natural Thyroid among the products concerned. A follow-up letter dated March 11, 2026 moved the timetable rather than the legal position: the agency said it is applying its general risk-based enforcement approach, giving priority to the products posing the highest risk to public health, and that it plans to issue draft guidance before August 2026 describing its compliance priorities and the conditions of continued enforcement discretion for these products.

Two consequences follow that a reader should not have to infer. Continued availability is not guaranteed: it currently rests on enforcement discretion the agency has said it intends to define in guidance, not on an approval. The agency has not withdrawn its underlying position that these products are unapproved and cannot be legally marketed in their present form. And compounded desiccated thyroid preparations are in the same position rather than an easier one; the FDA's stated view is that products subject to licensure under section 351 are not eligible for the compounding exemptions in sections 503A and 503B.

Professional guidance points the same way from a different direction. The American Thyroid Association task force reviewed thyroid extracts and compounded thyroid hormones alongside approved options and did not find evidence supporting their superiority.^[4] Older joint guidance from the same bodies states plainly that the standard treatment for hypothyroidism is replacement with L-thyroxine.^[2]

Product quality has been a documented problem rather than a theoretical one, and the recalls belong to this product by name. In May 2020 Acella Pharmaceuticals recalled thirteen lots of 30 mg, 60 mg and 90 mg NP Thyroid as superpotent, containing up to 115% of the labeled amount of liothyronine, with two adverse-event reports known at the time. In September 2020 it recalled two further lots, at 15 mg and 120 mg, as subpotent, containing as little as 87% of the labeled levothyroxine, with four reports. In April 2021 it recalled a larger set of lots across all five strengths as subpotent, containing less than 90% of the labeled liothyronine and/or levothyroxine, and reported 43 serious adverse events that could possibly be related. Both directions of error occurred in the same product within a year of each other. That is the concrete form of the batch-to-batch variability described above, and it is why the FDA's stated concerns about these products center on potency and content uniformity rather than on the hormones themselves.

Thyroid hormone is also, unavoidably, a drug that gets used outside its indication: for fatigue, for weight, for symptoms in people whose thyroid function is normal. Neither trial summarized above enrolled such a population, and the risks documented in the cohort literature are risks of excess thyroid hormone regardless of why it was taken.^[1]^[6]

Peptide Health Lab does not sell anything and does not tell anyone how to obtain any product. The reason regulatory status appears on this page at all is that it explains what evidence stands behind the tablet and what does not.

Questions to bring to a provider

Thyroid replacement is one of the few therapies where the right questions are almost entirely about measurement.

What is the actual diagnosis and its cause, and what were the thyrotropin and free thyroxine values that established it?^[10]
What is the target range for thyrotropin, and what is the reasoning behind that particular target?
When will thyrotropin be rechecked after any change, given that the reviewed practice is six to eight weeks after starting or adjusting and at least annually once at goal?^[10]
If desiccated thyroid is being considered instead of levothyroxine, what is the specific reason, and does it match the trials, which found equivalent symptoms and cognition but a real difference in preference?^[3]^[8]
Does the cardiac history, particularly any atrial fibrillation, angina, or coronary artery disease, change the target or the starting approach, given the association between low thyrotropin and later atrial fibrillation?^[1] Guideline literature describes lower starting doses specifically for older adults and for people with atrial fibrillation or coronary artery disease, and chest pain is among the effects reported when this product class is delivered at more than its labeled potency.^[2]
If any new or worsening chest pain, palpitations, or unexplained change in symptoms appears after a refill, is a repeat thyrotropin measurement warranted before assuming the dose is the explanation?^[10]
What is the plan for bone density monitoring over years of therapy, given the association between subclinical hyperthyroidism and femoral neck bone loss?^[6]
Which other medications and supplements affect absorption, and how should timing be arranged around them?
If symptoms persist despite a normal thyrotropin, what else is being investigated before the thyroid prescription is changed again?^[7]

A clinician who insists on repeat labs before and after any change to a thyroid prescription is doing the thing that makes this therapy safe.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Symptom relief and quality of life compared with levothyroxine

Human RCT evidence human RCT

Two randomized, double-blind crossover trials found no significant advantage. In 70 patients treated for 16 weeks per arm, there were no differences in symptoms or neurocognitive measurements between desiccated thyroid extract and levothyroxine. In a 75-patient three-arm trial run for 22 weeks per arm, there were no differences on the thyroid symptom questionnaire, general health questionnaire, memory scale, or depression inventory.

[3] [8]

Patient preference

Human RCT evidence human RCT · review

The most interesting finding in this literature, and the one most often over-read. In the 2013 crossover trial 48.6% of patients preferred desiccated thyroid extract, 18.6% preferred levothyroxine, and 32.9% had no preference, while measured symptoms and cognition did not differ. The 2021 trial found no overall preference difference, but the third of patients who were most symptomatic on levothyroxine strongly preferred a triiodothyronine-containing treatment. A meta-analysis of combination therapy similarly found 43% preferring combination against 23% preferring monotherapy.

[3] [8] [9]

Weight change

Human RCT evidence human RCT

Modest and consistently reported. Patients lost about 3 lb during the desiccated thyroid extract arm of the 2013 crossover trial, and those who went on to prefer it lost about 4 lb. This is a short-term average in treated hypothyroid patients under protocol, not a weight-loss indication, and thyroid hormone is not a weight-management drug.

[3]

Combination T4/T3 therapy in general

Human RCT evidence review

Fourteen clinical trials have not shown a consistent benefit of combining levothyroxine with liothyronine, and a joint consensus process concluded there is equipoise for a properly designed new trial rather than a resolved answer. A systematic review of 18 studies found no difference in clinical status, quality of life, psychological distress, depressive symptoms, or fatigue, at low-to-moderate certainty.

[7] [9]

Position within the standard of care

Anecdotal reports only review

Graded conservatively for the same reason as the entry below it. The American Thyroid Association task force reviewed levothyroxine, non-levothyroxine therapies including thyroid extracts and compounded thyroid hormones, and thyroid hormone analogs, and concluded that levothyroxine should remain the standard of care, finding no consistently strong evidence that any alternative preparation improves health outcomes. Earlier joint guidance likewise states the standard treatment is replacement with L-thyroxine. Both sources are guideline documents rather than trials reporting this outcome; they are task force recommendations synthesizing a literature. No randomized trial has ever compared "levothyroxine as standard of care" against an alternative standard as a tested strategy. The conclusion is the strongest expert reading of the evidence, which is not the same as being the evidence.

[4] [2]

Treatment of hypothyroidism itself

Anecdotal reports only review

Not in dispute, and worth stating so the rest of the page is read in context. Untreated hypothyroidism causes real harm, including progression to myxedema coma with a mortality rate of up to 30%, and first-line treatment is synthetic levothyroxine titrated to normalize thyrotropin. The open question about desiccated thyroid is whether it is better than that, not whether treating hypothyroidism is worthwhile. The grade is a statement about the citation rather than about the claim: the source here is a 2025 narrative review, and thyroid hormone replacement predates the randomized-trial era and has never been placebo-controlled against untreated overt hypothyroidism, for reasons that are ethical rather than scientific. Some things are well established without an RCT behind them, and this rubric grades the evidence type, not the confidence.

[10]

Long-term safety of running thyrotropin at the low end

Anecdotal reports only human observational

The evidence here is prospective cohort data rather than randomized trial data, and this library's three-grade scale has no observational tier, so it is graded conservatively. Low thyrotropin in older people predicted atrial fibrillation over 10 years, thyroid hormone therapy carried a markedly elevated hazard of thyrotoxicosis in an aging cohort, and subclinical hyperthyroidism was associated with faster femoral neck bone loss across six cohorts. No randomized trial has tested long-term outcomes of a deliberately low-normal target.

[1] [5] [6]

Claim area	Evidence & sources	What the research shows
Symptom relief and quality of life compared with levothyroxine	Human RCT evidence human RCT [3] [8]	Two randomized, double-blind crossover trials found no significant advantage. In 70 patients treated for 16 weeks per arm, there were no differences in symptoms or neurocognitive measurements between desiccated thyroid extract and levothyroxine. In a 75-patient three-arm trial run for 22 weeks per arm, there were no differences on the thyroid symptom questionnaire, general health questionnaire, memory scale, or depression inventory.
Patient preference	Human RCT evidence human RCT · review [3] [8] [9]	The most interesting finding in this literature, and the one most often over-read. In the 2013 crossover trial 48.6% of patients preferred desiccated thyroid extract, 18.6% preferred levothyroxine, and 32.9% had no preference, while measured symptoms and cognition did not differ. The 2021 trial found no overall preference difference, but the third of patients who were most symptomatic on levothyroxine strongly preferred a triiodothyronine-containing treatment. A meta-analysis of combination therapy similarly found 43% preferring combination against 23% preferring monotherapy.
Weight change	Human RCT evidence human RCT [3]	Modest and consistently reported. Patients lost about 3 lb during the desiccated thyroid extract arm of the 2013 crossover trial, and those who went on to prefer it lost about 4 lb. This is a short-term average in treated hypothyroid patients under protocol, not a weight-loss indication, and thyroid hormone is not a weight-management drug.
Combination T4/T3 therapy in general	Human RCT evidence review [7] [9]	Fourteen clinical trials have not shown a consistent benefit of combining levothyroxine with liothyronine, and a joint consensus process concluded there is equipoise for a properly designed new trial rather than a resolved answer. A systematic review of 18 studies found no difference in clinical status, quality of life, psychological distress, depressive symptoms, or fatigue, at low-to-moderate certainty.
Position within the standard of care	Anecdotal reports only review [4] [2]	Graded conservatively for the same reason as the entry below it. The American Thyroid Association task force reviewed levothyroxine, non-levothyroxine therapies including thyroid extracts and compounded thyroid hormones, and thyroid hormone analogs, and concluded that levothyroxine should remain the standard of care, finding no consistently strong evidence that any alternative preparation improves health outcomes. Earlier joint guidance likewise states the standard treatment is replacement with L-thyroxine. Both sources are guideline documents rather than trials reporting this outcome; they are task force recommendations synthesizing a literature. No randomized trial has ever compared "levothyroxine as standard of care" against an alternative standard as a tested strategy. The conclusion is the strongest expert reading of the evidence, which is not the same as being the evidence.
Treatment of hypothyroidism itself	Anecdotal reports only review [10]	Not in dispute, and worth stating so the rest of the page is read in context. Untreated hypothyroidism causes real harm, including progression to myxedema coma with a mortality rate of up to 30%, and first-line treatment is synthetic levothyroxine titrated to normalize thyrotropin. The open question about desiccated thyroid is whether it is better than that, not whether treating hypothyroidism is worthwhile. The grade is a statement about the citation rather than about the claim: the source here is a 2025 narrative review, and thyroid hormone replacement predates the randomized-trial era and has never been placebo-controlled against untreated overt hypothyroidism, for reasons that are ethical rather than scientific. Some things are well established without an RCT behind them, and this rubric grades the evidence type, not the confidence.
Long-term safety of running thyrotropin at the low end	Anecdotal reports only human observational [1] [5] [6]	The evidence here is prospective cohort data rather than randomized trial data, and this library's three-grade scale has no observational tier, so it is graded conservatively. Low thyrotropin in older people predicted atrial fibrillation over 10 years, thyroid hormone therapy carried a markedly elevated hazard of thyrotoxicosis in an aging cohort, and subclinical hyperthyroidism was associated with faster femoral neck bone loss across six cohorts. No randomized trial has tested long-term outcomes of a deliberately low-normal target.

Typical protocol range in the research

Randomized, double-blind, crossover trial in 70 adults aged 18 to 65 with primary hypothyroidism who had been on a stable levothyroxine dose for at least six months

Sixteen weeks on desiccated thyroid extract and sixteen weeks on levothyroxine, each at doses set to biochemical targets rather than to a fixed amount. The trial defines adequacy by serum thyrotropin, not by tablet strength [3]
Prospective, randomized, double-blind, three-arm crossover trial in 75 hypothyroid patients comparing levothyroxine, levothyroxine plus liothyronine, and desiccated thyroid extract

Twenty-two weeks in each arm, with serum thyrotropin held within the reference range across all three treatments [8]
Guideline and review literature on thyroid hormone replacement generally

No fixed research range exists. Replacement is titrated by a prescriber against serum thyrotropin measured six to eight weeks after starting or changing a dose and at least annually once at goal, with lower starting doses described for older adults and for people with atrial fibrillation or coronary artery disease [10] [2]

This is the one compound in the library where the honest protocol answer is that there is no protocol to report. Thyroid hormone replacement is dosed to a laboratory target that is specific to a person's biochemistry, adjusted in small increments, and re-checked on a schedule. The trials above worked the same way. Any figure lifted from a trial arm without the accompanying thyrotropin measurement is meaningless. Desiccated thyroid extract and levothyroxine are also not bioequivalent and are not interchangeable unit for unit: they differ in composition, since the extract supplies triiodothyronine as well as thyroxine, and neither randomized trial above used a fixed conversion between them; each re-titrated every participant against a thyrotropin target after switching. Moving between the two is a fresh titration with its own laboratory follow-up, not a substitution.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

Iatrogenic thyrotoxicosis from over-replacement

Low thyrotropin was present in 9.6% of people taking thyroid hormone versus 0.8% of untreated participants in an aging cohort; new cases arose at 17.7 per 1,000 person-years of exposure versus 1.5 per 1,000 in the unexposed · Over-replacement is the characteristic harm of this drug class and it is often silent. In the same cohort the adjusted hazard ratio for thyrotoxicosis between treated and untreated women was 27.5, and women were both more likely to be treated and more often overtreated than men. This is the mechanism by which a hormone intended to correct a deficiency produces the opposite state, and it is detected by a blood test rather than by how someone feels.

[5]
Atrial fibrillation associated with a suppressed thyrotropin

28% cumulative 10-year incidence among people aged 60 or older whose thyrotropin was 0.1 mU/L or below, versus 11% with normal values · A prospective cohort of 2,007 clinically euthyroid older people found that a low serum thyrotropin was a risk factor for later atrial fibrillation, with an age-adjusted incidence of 28 per 1,000 person-years against 10 per 1,000 in those with normal values. Existing arrhythmia or cardiac disease is a specific reason to discuss both the target range and the monitoring interval before any change.

[1]
Accelerated bone loss when thyrotropin runs low

Greater annual femoral neck bone loss in subclinical hyperthyroidism across six prospective cohorts and 5,458 individuals · An individual-participant analysis found an annualized femoral neck bone mineral density change of -0.18% in subclinical hyperthyroidism relative to euthyroidism, most pronounced when thyrotropin fell below 0.10 mIU/L, with no significant effect at the lumbar spine. The magnitude per year is small; the exposure in a person on lifelong replacement is not.

[6]
Higher heart rate on desiccated thyroid than on levothyroxine

A minor increase reported in the three-arm randomized crossover trial · In an otherwise null comparison across levothyroxine, levothyroxine plus liothyronine, and desiccated thyroid extract, the one measured difference attributable to desiccated thyroid was a small rise in heart rate. It is consistent with the product delivering triiodothyronine directly, and it is the kind of finding that matters more for someone with cardiac disease than for the average trial participant.

[8]
Cardiovascular risk from both over- and under-replacement

Not expressed as a rate; described as a general treatment risk · A recent review states that thyrotropin should be checked six to eight weeks after starting or changing thyroid hormone and annually once at goal specifically to avoid overtreatment or undertreatment, both of which are associated with cardiovascular health risks. The monitoring schedule is not administrative caution. It is the safety mechanism of the therapy.

[10]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage: NP Thyroid is not a lyophilized preparation. It is supplied as an oral tablet and kept as the dispensed container's labeling states: conventionally controlled room temperature, away from heat, light, and moisture, in the original closed container. Because tablet strengths look similar and this is a hormone titrated in small increments, keeping the product in its labeled container rather than a combined organizer is the handling detail that actually matters.
Reconstitution: Not applicable. NP Thyroid is supplied as an oral tablet; there is nothing to reconstitute. No diluent, no vial, and no preparation step is involved.
Handling notes: The consequential handling question for desiccated thyroid is not storage but identity: the strength dispensed, the specific product, and whether anything about the prescription changed at the pharmacy. Thyroid hormone is absorbed variably in the presence of food, calcium, iron, and several common medications, so timing relative to other things taken is a pharmacist and prescriber conversation rather than a general rule that can be published on a reference page.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Goal pages that include NP Thyroid

Each one starts from the goal rather than the molecule, and grades what the evidence supports for that goal specifically.

Cognitive Function
An honest map of a goal this library cannot serve. No compound reviewed on this site has human evidence of improving cognition, and the three that were tested against a cognitive endpoint each returned a null result.
Hair
A research reference for the compounds people map to hair loss and hair growth, including the finding that the copper-peptide hair study everyone cites tested a different peptide, and that nothing in this library has a published human efficacy result for hair.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

10 sources · every identifier checked against PubMed

[1] Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons · New England Journal of Medicine, 1994. Human observational study
[2] Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association · Thyroid, 2012. Review
[3] Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study · Journal of Clinical Endocrinology and Metabolism, 2013. Human RCT
[4] Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement · Thyroid, 2014. Review
[5] Thyroid Hormone Therapy and Risk of Thyrotoxicosis in Community-Resident Older Adults: Findings from the Baltimore Longitudinal Study of Aging · Thyroid, 2015. Human observational study
[6] Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts · Journal of Internal Medicine, 2018. Human observational study
[7] Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document · Thyroid, 2021. Review
[8] Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism · Journal of Clinical Endocrinology and Metabolism, 2021. Human RCT
[9] Benefits and Harms of Levothyroxine/L-Triiodothyronine Versus Levothyroxine Monotherapy for Adult Patients with Hypothyroidism: Systematic Review and Meta-Analysis · Thyroid, 2021. Review
[10] Hypothyroidism: A Review · JAMA, 2025. Review

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder